Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Mesenchymal Stem Cells From Adipose Tissue Do not Improve Functional Recovery After Ischemic Stroke in Hypertensive Rats.

Diekhorst L, Gómez-de Frutos MC, Laso-García F, Otero-Ortega L, Fuentes B, Jolkkonen J, Detante O, Moisan A, Leyva L, Martínez-Arroyo A, Díez-Tejedor E, Gutiérrez-Fernández M; RESSTORE Consortium.

Stroke. 2019 Nov 7:STROKEAHA119027133. doi: 10.1161/STROKEAHA.119.027133. [Epub ahead of print]

PMID:
31694504
2.

Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease.

Vilariño-Güell C, Zimprich A, Martinelli-Boneschi F, Herculano B, Wang Z, Matesanz F, Urcelay E, Vandenbroeck K, Leyva L, Gris D, Massaad C, Quandt JA, Traboulsee AL, Encarnacion M, Bernales CQ, Follett J, Yee IM, Criscuoli MG, Deutschländer A, Reinthaler EM, Zrzavy T, Mascia E, Zauli A, Esposito F, Alcina A, Izquierdo G, Espino-Paisán L, Mena J, Antigüedad A, Urbaneja-Romero P, Ortega-Pinazo J, Song W, Sadovnick AD.

PLoS Genet. 2019 Jun 6;15(6):e1008180. doi: 10.1371/journal.pgen.1008180. eCollection 2019 Jun.

3.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.

PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018.

4.

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, Ortega-Pinazo J, Serrano P, Fernández Ó, Leyva L, Oliver-Martos B.

Sci Rep. 2017 Nov 29;7(1):16585. doi: 10.1038/s41598-017-16828-x.

5.

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.

Pinto-Medel MJ, Oliver-Martos B, Urbaneja-Romero P, Hurtado-Guerrero I, Ortega-Pinazo J, Serrano-Castro P, Fernández Ó, Leyva L.

Sci Rep. 2017 Aug 18;7(1):8727. doi: 10.1038/s41598-017-09301-2.

6.

The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.

Alvarenga MP, Fernandez O, Leyva L, Campanella L, Vasconcelos CF, Alvarenga M, Papais Alvarenga RM.

J Neuroimmunol. 2017 Sep 15;310:1-7. doi: 10.1016/j.jneuroim.2017.05.018. Epub 2017 May 31.

PMID:
28778431
7.

Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.

Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, Fernández Ó, Leyva L, Oliver-Martos B.

PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017.

8.

Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.

Marin-Bañasco C, Benabdellah K, Melero-Jerez C, Oliver B, Pinto-Medel MJ, Hurtado-Guerrero I, de Castro F, Clemente D, Fernández O, Martin F, Leyva L, Suardíaz M.

Br J Pharmacol. 2017 Feb;174(3):238-253. doi: 10.1111/bph.13674. Epub 2017 Jan 12.

9.

Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.

Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B.

Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9.

PMID:
27613121
10.

Month of birth, HLA-DRB1*15 locus and risk of multiple sclerosis in offspring.

Guijarro-Castro C, Sanchez-Zapardiel E, Munoz D, Fernandez O, Leyva L, Castro-Panete MJ, Picon-Munoz C, Talise M, Martinez-Feito A, Paz-Artal E.

Rev Neurol. 2016 Sep 1;63(5):201-5. English, Spanish.

11.

Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.

Suardíaz M, Clemente D, Marin-Bañasco C, Orpez T, Hurtado-Guerrero I, Pavía J, Pinto-Medel MJ, De Castro F, Leyva L, Fernández O, Oliver B.

Neuropharmacology. 2016 Nov;110(Pt A):480-492. doi: 10.1016/j.neuropharm.2016.07.026. Epub 2016 Jul 22.

PMID:
27452720
12.

Cell-based product classification procedure: What can be done differently to improve decisions on borderline products?

Izeta A, Herrera C, Mata R, Astori G, Giordano R, Hernández C, Leyva L, Arias S, Oyonarte S, Carmona G, Cuende N.

Cytotherapy. 2016 Jul;18(7):809-15. doi: 10.1016/j.jcyt.2016.03.292. Epub 2016 May 18. Review.

PMID:
27209278
13.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

14.

Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis.

Órpez-Zafra T, Pavía J, Pinto-Medel MJ, Hurtado-Guerrero I, Rodriguez-Bada JL, Martín Montañez E, Fernández Ó, Leyva L, Oliver-Martos B.

Bioanalysis. 2015;7(22):2869-80. doi: 10.4155/bio.15.208. Epub 2015 Nov 16.

15.

Genome-wide significant association with seven novel multiple sclerosis risk loci.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, Fernández O, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L.

J Med Genet. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16.

PMID:
26475045
16.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

17.

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

Matesanz F, Potenciano V, Fedetz M, Ramos-Mozo P, Abad-Grau Mdel M, Karaky M, Barrionuevo C, Izquierdo G, Ruiz-Peña JL, García-Sánchez MI, Lucas M, Fernández Ó, Leyva L, Otaegui D, Muñoz-Culla M, Olascoaga J, Vandenbroeck K, Alloza I, Astobiza I, Antigüedad A, Villar LM, Álvarez-Cermeño JC, Malhotra S, Comabella M, Montalban X, Saiz A, Blanco Y, Arroyo R, Varadé J, Urcelay E, Alcina A.

Hum Mol Genet. 2015 Oct 1;24(19):5619-27. doi: 10.1093/hmg/ddv256. Epub 2015 Jul 7.

PMID:
26152201
18.

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.

López-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, Fernández Ó, Leyva L.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3.

19.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.

Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30.

PMID:
25581547
20.

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands.

Delgado-García M, Matesanz F, Alcina A, Fedetz M, García-Sánchez MI, Ruiz-Peña JL, Fernández Ó, Pinto Medel MJ, Leyva L, Arnal C, Delgado C, López Guerrero JA, González-Pérez A, Sáez ME, Villar LM, Álvarez-Cermeño JC, Picón C, Arroyo R, Varadé J, Urcelay E, Izquierdo G, Lucas M.

Mult Scler. 2015 Aug;21(9):1104-11. doi: 10.1177/1352458514556302. Epub 2014 Nov 12.

21.

Accumulation of fatty acids in Chlorella vulgaris under heterotrophic conditions in relation to activity of acetyl-CoAcarboxylase, temperature, and co-immobilization with Azospirillum brasilense [corrected].

Leyva LA, Bashan Y, Mendoza A, de-Bashan LE.

Naturwissenschaften. 2014 Oct;101(10):819-30. doi: 10.1007/s00114-014-1223-x. Epub 2014 Aug 17. Erratum in: Naturwissenschaften. 2014 Dec;101(12):1115.

PMID:
25129521
22.

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, Montalbán X, Fernández O, Oliver-Martos B, Leyva L, Comabella M, Urcelay E.

J Med Genet. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348. Epub 2014 Apr 19.

PMID:
24748646
23.

Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response.

García-León JA, López-Gómez C, Orpez-Zafra T, Reyes-Garrido V, Marín-Bañasco C, Oliver-Martos B, Fernández O, Leyva L.

CNS Drugs. 2014 Jun;28(6):559-70. doi: 10.1007/s40263-014-0153-7.

PMID:
24599774
24.

Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis.

de la Hera B, Varadé J, García-Montojo M, Alcina A, Fedetz M, Alloza I, Astobiza I, Leyva L, Fernández O, Izquierdo G, Antigüedad A, Arroyo R, Álvarez-Lafuente R, Vandenbroeck K, Matesanz F, Urcelay E.

PLoS One. 2014 Mar 3;9(3):e90182. doi: 10.1371/journal.pone.0090182. eCollection 2014.

25.

Early development of anti-natalizumab antibodies in MS patients.

Oliver-Martos B, Órpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, Fernández O.

J Neurol. 2013 Sep;260(9):2343-7. doi: 10.1007/s00415-013-6991-2. Epub 2013 Jun 14.

PMID:
23765090
26.

Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L.

PLoS One. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013.

27.

Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis.

Alcina A, Fedetz M, Fernández O, Saiz A, Izquierdo G, Lucas M, Leyva L, García-León JA, Abad-Grau Mdel M, Alloza I, Antigüedad A, Garcia-Barcina MJ, Vandenbroeck K, Varadé J, de la Hera B, Arroyo R, Comabella M, Montalban X, Petit-Marty N, Navarro A, Otaegui D, Olascoaga J, Blanco Y, Urcelay E, Matesanz F.

J Med Genet. 2013 Jan;50(1):25-33. doi: 10.1136/jmedgenet-2012-101085. Epub 2012 Nov 17.

28.

Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1.

Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, Zara I, Pitzalis M, Cavanillas ML, Arroyo R, Zoledziewska M, Marrosu M, Fernández O, Leyva L, Alcina A, Fedetz M, Moreno-Rey C, Velasco J, Real LM, Ruiz-Peña JL, Cucca F, Ruiz A, Izquierdo G.

PLoS One. 2012;7(5):e36140. doi: 10.1371/journal.pone.0036140. Epub 2012 May 3.

29.

DRB1*03:01 haplotypes: differential contribution to multiple sclerosis risk and specific association with the presence of intrathecal IgM bands.

de la Concha EG, Cavanillas ML, Cénit MC, Urcelay E, Arroyo R, Fernández Ó, Álvarez-Cermeño JC, Leyva L, Villar LM, Núñez C.

PLoS One. 2012;7(2):e31018. doi: 10.1371/journal.pone.0031018. Epub 2012 Feb 17.

30.

The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis.

Pinto-Medel MJ, García-León JA, Oliver-Martos B, López-Gómez C, Luque G, Arnáiz-Urrutia C, Orpez T, Marín-Bañasco C, Fernández O, Leyva L.

J Neuroimmunol. 2012 Feb 29;243(1-2):1-11. doi: 10.1016/j.jneuroim.2011.11.008. Epub 2012 Jan 20.

PMID:
22261542
31.

ANKRD55 and DHCR7 are novel multiple sclerosis risk loci.

Alloza I, Otaegui D, de Lapuente AL, Antigüedad A, Varadé J, Núñez C, Arroyo R, Urcelay E, Fernandez O, Leyva L, Fedetz M, Izquierdo G, Lucas M, Oliver-Martos B, Alcina A, Saiz A, Blanco Y, Comabella M, Montalban X, Olascoaga J, Matesanz F, Vandenbroeck K.

Genes Immun. 2012 Apr;13(3):253-7. doi: 10.1038/gene.2011.81. Epub 2011 Dec 1.

PMID:
22130326
32.

Autologous stem cells for the treatment of post-mastectomy lymphedema: a pilot study.

Maldonado GE, Pérez CA, Covarrubias EE, Cabriales SA, Leyva LA, Pérez JC, Almaguer DG.

Cytotherapy. 2011 Nov;13(10):1249-55. doi: 10.3109/14653249.2011.594791.

PMID:
21999374
33.

IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis.

Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E, Fernández O, Drulovic J, García-Merino A, Martinelli Boneschi F, Chan A, Vandenbroeck K, Navarro A, Bustamante MF, Río J, Akkad DA, Giacalone G, Sánchez AJ, Leyva L, Alvarez-Lafuente R, Zettl UK, Oksenberg J, Montalban X, Comabella M.

J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1.

PMID:
21889215
34.

TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.

López-Gómez C, Fernández O, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardíaz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L.

PLoS One. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21.

35.

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.

Oliver B, Fernández O, Orpez T, Alvarenga MP, Pinto-Medel MJ, Guerrero M, León A, López-Madrona JC, Maldonado-Sánchez R, García-León JA, Luque G, Fernández V, Leyva L.

Mult Scler. 2011 Mar;17(3):368-71. doi: 10.1177/1352458510385508. Epub 2010 Dec 21.

PMID:
21177326
36.

Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients.

Oliver-Martos B, Órpez T, Pinto-Medel MJ, Mayorga C, García-León JA, Maldonado-Sanchez R, Suardíaz M, Guerrero M, Luque G, Leyva L, Fernández O.

J Neuroimmunol. 2011 Jan;230(1-2):153-9. doi: 10.1016/j.jneuroim.2010.10.033. Epub 2010 Nov 24.

PMID:
21106255
37.

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V.

Mult Scler. 2011 Feb;17(2):192-7. doi: 10.1177/1352458510385507. Epub 2010 Nov 18.

PMID:
21088044
38.

Replication of top markers of a genome-wide association study in multiple sclerosis in Spain.

Cavanillas ML, Fernández O, Comabella M, Alcina A, Fedetz M, Izquierdo G, Lucas M, Cénit MC, Arroyo R, Vandenbroeck K, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Gómez CL, Olascoaga J, Otaegui D, Blanco Y, Saiz A, Montalbán X, Matesanz F, Urcelay E.

Genes Immun. 2011 Mar;12(2):110-5. doi: 10.1038/gene.2010.52. Epub 2010 Oct 14.

PMID:
20944657
39.

The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis.

Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O, Cavanillas ML, Cénit MC, Arroyo R, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Izquierdo G, Lucas M, Fedetz M, Pinto-Medel MJ, Olascoaga J, Blanco Y, Comabella M, Montalban X, Urcelay E, Matesanz F.

Genes Immun. 2010 Jul;11(5):439-45. doi: 10.1038/gene.2010.30. Epub 2010 May 27.

PMID:
20508602
40.

Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis.

Alcina A, Fernández O, Gonzalez JR, Catalá-Rabasa A, Fedetz M, Ndagire D, Leyva L, Guerrero M, Arnal C, Delgado C, Lucas M, Izquierdo G, Matesanz F.

Eur J Hum Genet. 2010 Jul;18(7):827-31. doi: 10.1038/ejhg.2009.240. Epub 2010 Jan 20.

41.

Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis.

Alcina A, Ramagopalan SV, Fernández O, Catalá-Rabasa A, Fedetz M, Ndagire D, Leyva L, Arnal C, Delgado C, Lucas M, Izquierdo G, Ebers GC, Matesanz F.

Eur J Hum Genet. 2010 May;18(5):618-20. doi: 10.1038/ejhg.2009.213. Epub 2009 Nov 25.

42.

Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection.

Oliver B, Orpez T, Mayorga C, Pinto-Medel MJ, Leyva L, López-Gómez C, Marín C, Luque G, Ortega-Pinazo J, Fernández O.

J Immunol Methods. 2009 Dec 31;351(1-2):41-5. doi: 10.1016/j.jim.2009.09.005. Epub 2009 Sep 25.

PMID:
19786034
43.

Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis.

Vasconcelos CC, Fernández O, Leyva L, Thuler LC, Alvarenga RM.

J Neuroimmunol. 2009 Sep 29;214(1-2):101-3. doi: 10.1016/j.jneuroim.2009.06.009. Epub 2009 Jul 17.

PMID:
19616314
44.

HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain).

Fernández O, R-Antigüedad A, Pinto-Medel MJ, Mendibe MM, Acosta N, Oliver B, Guerrero M, Papais-Alvarenga M, Fernández-Sánchez V, Leyva L.

J Neurol. 2009 Dec;256(12):1977-88. doi: 10.1007/s00415-009-5223-2.

PMID:
19585166
45.

Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population.

Fedetz M, Ndagire D, Fernandez O, Leyva L, Guerrero M, Arnal C, Lucas M, Izquierdo G, Delgado C, Alcina A, Matesanz F.

Tissue Antigens. 2009 Sep;74(3):244-7. doi: 10.1111/j.1399-0039.2009.01298.x. Epub 2009 Jun 11.

PMID:
19523143
46.

Serum cytokines, mood and sleep after a qigong program: is qigong an effective psychobiological tool?

Manzaneque JM, Vera FM, Rodriguez FM, Garcia GJ, Leyva L, Blanca MJ.

J Health Psychol. 2009 Jan;14(1):60-7. doi: 10.1177/1359105308097946.

PMID:
19129338
47.

IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).

Alcina A, Fedetz M, Ndagire D, Fernández O, Leyva L, Guerrero M, Abad-Grau MM, Arnal C, Delgado C, Lucas M, Izquierdo G, Matesanz F.

PLoS One. 2009;4(1):e4137. doi: 10.1371/journal.pone.0004137. Epub 2009 Jan 6.

48.

The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis.

Alcina A, Fedetz M, Ndagire D, Fernández O, Leyva L, Guerrero M, Arnal C, Delgado C, Matesanz F.

Tissue Antigens. 2008 Aug;72(2):158-61. doi: 10.1111/j.1399-0039.2008.01075.x.

PMID:
18721276
49.

Activity of two catabolic enzymes of the phosphogluconate pathway in mesquite roots inoculated with Azospirillum brasilense Cd.

Leyva LA, Bashan Y.

Plant Physiol Biochem. 2008 Oct;46(10):898-904. doi: 10.1016/j.plaphy.2008.05.011. Epub 2008 Jun 20.

PMID:
18619846
50.

The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis.

Matesanz F, Fernández O, Milne RL, Fedetz M, Leyva L, Guerrero M, Delgado C, Lucas M, Izquierdo G, Alcina A.

J Neuroimmunol. 2008 Mar;195(1-2):146-50. doi: 10.1016/j.jneuroim.2008.01.004. Epub 2008 Mar 3.

PMID:
18313765

Supplemental Content

Support Center